Global Blood Therapeutics, Inc.
NASDAQ: GBT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ted Love
- Employees
- 457
- Headquarters
- South San Francisco, United States
- IPO year
- 2015
- Website
- https://www.gbt.com
Loading GBT…
Loading profile data…Frequently asked questions about GBT
What does Global Blood Therapeutics, Inc. (GBT) do?
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical firm dedicated to discovering, developing, and providing therapies for patients suffering from sickle cell disease (SCD) who currently lack adequate treatment options. Its marketed product, Oxbryta tablets, offers a once-daily, oral treatment for SCD. Furthermore, GBT is conducting a P...
Where does GBT trade?
Global Blood Therapeutics, Inc. (GBT) trades on the NASDAQ Global Select.
What sector is GBT in?
Global Blood Therapeutics, Inc. (GBT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Global Blood Therapeutics, Inc.?
Ted Love is the chief executive officer of Global Blood Therapeutics, Inc. (GBT).
Where is Global Blood Therapeutics, Inc. headquartered?
Global Blood Therapeutics, Inc. is headquartered in United States.
Does GBT pay a dividend?
Global Blood Therapeutics, Inc. (GBT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GBT go public?
Global Blood Therapeutics, Inc. (GBT) completed its initial public offering in 2015.